rs121918385 — APOB APOB Glu4034fs

APOB Frameshift — The Rare Mutation That Slashes LDL and Rewires Liver Fat

Apolipoprotein B (apoB) is the structural backbone of every VLDL and LDL particle in your bloodstream. Without functional apoB-100, the liver cannot package and export fats into the circulation. The rs121918385 variant is a 1-base-pair deletion in APOB exon 26 that truncates the apoB protein at approximately position 4040 — producing a severely shortened protein that cannot be lipidated or secreted normally. Carriers are clinically defined as having familial hypobetalipoproteinemia (FHBL)¹¹ familial hypobetalipoproteinemia (FHBL)
a dominantly inherited disorder characterized by LDL cholesterol below the 5th percentile for age and sex, typically 20–50 mg/dL in heterozygotes.

The Mechanism

The deletion removes a single cytosine from the glutamic acid codon at position 4034, shifting the reading frame. The altered sequence encodes arginine at position 4034 then hits a premature stop codon seven residues later (p.Glu4034ArgfsTer7). The truncated mRNA is partially degraded by nonsense-mediated decay²² nonsense-mediated decay
a cellular surveillance mechanism that destroys transcripts with premature stop codons, reducing total functional apoB-100 output from the mutant allele. What survives is a shortened protein representing roughly 88% of full-length apoB that cannot be efficiently assembled into VLDL particles.

Linton, Pierotti & Young 1992³³ Linton, Pierotti & Young 1992
Reading-frame restoration with an apolipoprotein B gene frameshift mutation. PNAS 89(23):11431–5 described the molecular mechanism in detail and observed an unusual compensatory feature: transcriptional slippage at the polyadenosine stretch created by the deletion can occasionally insert an extra adenine, restoring the reading frame and allowing some full-length apoB to be produced from the mutant allele. This partial compensation is why the phenotype is less severe than complete absence of apoB.

The Evidence

Cardiovascular protection. The most clinically striking consequence of APOB truncating variants is profound protection against coronary heart disease. Peloso et al. 2019⁴⁴ Peloso et al. 2019
Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circ Genomic Precis Med sequenced APOB in 57,973 participants (18,442 with early-onset CHD, 39,531 controls). Carriers of any APOB protein-truncating variant had 43 mg/dL lower LDL-C and 72% lower risk for CHD (OR 0.28, 95% CI 0.12–0.64, P=0.002). This is the strongest genetic evidence that lifelong low LDL directly prevents coronary disease.

Hepatic fat accumulation. Fat that cannot be exported as LDL accumulates in the liver. Heterozygotes have a 3–5 fold increase in hepatic fat content compared to controls and a 54% prevalence of hepatic steatosis on ultrasound in longitudinal studies. Progression to steatohepatitis, fibrosis, or cirrhosis is uncommon but occurs in approximately 5–10% of heterozygotes, particularly in those with additional metabolic risk factors such as high caloric intake or alcohol use.

Fat-soluble vitamins. Because fat absorption depends partly on LDL-sized particles for vitamin transport from the gut, heterozygotes have measurably lower plasma vitamin E levels (~50% of controls in Clarke et al. 2006⁵⁵ Clarke et al. 2006
Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia. Clin Chem 52(7):1339-45). However, the same study found no increase in oxidative stress biomarkers, and concluded that routine vitamin E supplementation is not warranted for heterozygotes. In biallelic (homozygous) carriers, fat-soluble vitamin deficiency is severe and requires high-dose supplementation.

Practical Actions

Heterozygous carriers benefit primarily from cardiovascular surveillance to confirm the expected protection is present, and liver monitoring to detect the minority who develop clinically meaningful steatosis. The actionable difference from the general population is threefold: (1) cardiovascular risk scoring should be recalibrated because standard LDL-based risk equations substantially overestimate risk at these LDL levels; (2) liver health — not lipid-lowering — becomes the primary metabolic concern; (3) fat-soluble vitamin levels should be checked periodically given reduced plasma transport.

Homozygous carriers (extremely rare, prevalence <1:1,000,000) require subspecialty management with high-dose fat-soluble vitamins and low-fat dietary modification — essentially the same protocol as abetalipoproteinemia.

Interactions

APOB-FHBL heterozygosity can occur alongside APOE variants (rs429358, rs7412) that affect LDL clearance via an independent receptor pathway. In compound carriers of APOB-FHBL and APOE4, the APOE4-driven impairment of LDL receptor binding partially offsets the APOB production deficit — LDL levels may be in the low-normal range rather than very low, potentially obscuring the FHBL diagnosis on routine lipid panels and warranting apoB protein electrophoresis to detect the truncated isoform.